What's new? Log in Free sign up

Valneva SE (VALN)

Company Profile

Company profile

Ticker

VALN

Exchange

Website

CEO

Mr. Thomas Lingelbach

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Biomotion Sciences Ordinary Shares • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Moderna • Bio-Techne • Acorda Therapeutics • Mach Natural Resources ...

Former names

Flying Eagle Acquisition Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

VALN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

Current report (foreign)

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

Transcripts

Earnings call transcript

Earnings call transcript

Latest ownership filings

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Bpifrance Participations SA

Deep Track Capital, LP

Bpifrance Participations SA

Financial summary

Financial statements Chart VALN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Valneva SE earnings reports.

Institutional ownership, Q2 2024

VALN institutional ownership history Ownership history

26.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	6	13	-53.8%
Opened positions	2	11	-81.8%
Closed positions	9	0	NEW
Increased positions	1	0	NEW
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	1.26 bn	4.20 bn	-70.1%
Total shares	21.26 mm	21.62 mm	-1.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Bpifrance Participations	11.62 mm	$365.23 mm	0.0%
PFE Pfizer	9.55 mm	$237.31 mm	0.0%
AlphaCentric Advisors	88.25 k	$648.65 mm	+42.3%
Ridgewood Investments	550.00	$3.86 mm	NEW
Allworth Financial	7.00	$53.00 k	0.0%
Activest Wealth Management	1.00	$7.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
GAM General American Investors	0.00	-354.36 k	EXIT
AlphaCentric Advisors	88.25 k	+26.25 k	+42.3%
Ironwood Investment Management	0.00	-25.02 k	EXIT
MS Morgan Stanley	0.00	-5.47 k	EXIT
WFC Wells Fargo & Company	0.00	-2.52 k	EXIT
UBS UBS	0.00	-962.00	EXIT
Ridgewood Investments	550.00	+550.00	NEW
Federation des caisses Desjardins du Quebec	0.00	-200.00	EXIT
Advisor	0.00	-150.00	EXIT
Qube Research & Technologies	0.00	-22.00	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Valneva USA Has Been Awarded A Maximum $49,297,248 Firm-Fixed-Price, Indefinite-Delivery/Indefinite-Quantity Contract For The Japanese Encephalitis Virus Vaccine

https://www.defense.gov/News/Contracts/Contract/Article/4047048/ Valneva USA Inc.,* Bethesda, Maryland, has been awarded a maximum $49,297,248 firm-fixed-price, indefinite-delivery/indefinite-quantity contract

HC Wainwright & Co. Maintains Buy on Valneva, Lowers Price Target to $18

HC Wainwright & Co. analyst Edward White maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $19 to $18.

Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

Reported Monday, Valneva Reports 98.3% Seroresponse One Year After Single Chikungunya Vaccine In Adolescents

Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday

Press releases

From Benzinga Pro

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million

Saint Herblain (France), January 30, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

Saint-Herblain (France), January 22, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

Saint-Herblain (France), January 20, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV)

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.